The Week in Endocrinology Oral Ozempic & Emerging Therapies
Oral Ozempic Launch, Semaglutide for Alcohol Use Disorder (Lancet RCT), and Canada’s First Generic Semaglutide | Week Ending May 8, 2026
...
Hormone Insight
Share:
Listens: 353
About
Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.
Week in Diabetes & Endocrinology (May 4, 2026): AID in Pregnancy, Tirzepatide ICERs, AACE Signals, Dapagliflozin & Anemia, Hypoglycemia Models, Oat Diet Trial
This episode reviews key diabetes/endocrinology updates for the week ending May 1, 2026: FDA clearance of Tandem Control-IQ Plus automat...
HORMONE INSIGHT -- THE WEEK IN DIABETES & ENDOCRINOLOGY -- Episode 004 | April 24, 2026
The Week in Diabetes & Endocrinology — Episode 004 | April 24, 2026
From Hormone Insight (hormoneinsight.com)
Six stories th...
The Week in Diabetes and Endocrinology April 17, 2026
The Week in Diabetes & Endocrinology — Episode 003 | April 17, 2026
From Hormone Insight (hormoneinsight.com)
Six stories th...
Episode 002: LDL Under 55 Wins Big, Medicare Covers GLP-1, and Second Weekly Insulin Emerges -- The Week in Diabetes & Endocrinology (April 10, 2026)
The Week in Diabetes & Endocrinology — Episode 002 | April 10, 2026
From Hormone Insight (hormoneinsight.com)
Six stories ...
From Hormone Insight (hormoneinsight.com)
Six stories ...
The Week in Diabetes and Endocrinology -- April 3, 2026
The Week in Diabetes & Endocrinology — Episode 001 | April 3, 2026
From Hormone Insight (hormoneinsight.com)
Six stories thi...
Early Onset Type 2 Diabetes and Tirzepatide (SURPASS Post Hoc Analysis)
In this episode of Hormone Insight, we examine a 2024 post hoc analysis published in Diabetes Care.
Exploring Semaglutide: Therapy for Obesity and Heart Failure
Exploring Semaglutide: Dual Action Therapy for Obesity and Heart Failure
Semaglutide vs Canagliflozin for Type 2 Diabetes
In this episode of Hormone Insight, we delve into a major study published in The Lancet Diabetes and Endocrin...
Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composi...